


SEQENS

Seqens

BioTuesdays Lyon



CONTINUUM OF PROGRESS

2.07.19

Seqens is a global player in pharmaceutical synthesis and specialty ingredients




3,200
Employees



€ 1bn
2018E Sales



1000+
Customers




24
Manufacturing sites



3 R&D centers
300 scientists & experts



2 main activities supported by transverse technologies range, R&D skills and global assets




 % of total EBITDA




Pharmaceuticals : Seqens supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase

Small molecules CDMO



Strong pipeline of clinical Phase programs to fuel future growth

~60 Customers Clinical phase programs



High-quality and differentiated specialty ingredients used in innovative and fast-growing applications

LARGE RANGE OF SPECIALTY INGREDIENTS ...

... with very high quality standards ...

...Used in cutting edge technologies and fast growing segments

Advanced Polymers

- **Ultra high purity**
- Low metal content

ELECTRONICS



OLED Display



Organic Photovoltaics

AEROSPACE



3D-printed aerostructure

Mineral Specialties

- **Pharma grade** (very low impurities, metals & sulphates)
- Large particle size range to address the broadest market potential

HEALTHCARE



Dialysis

PERSONAL CARE

Dry shampoos, bath bombs and scrubs

FOOD



pH stabilizer in organic energy drinks

Specialty solvents

- **Ultra high purity grades** produced under pharma quality standards
- **Natural-based** solvents
- Low VOCs solvents

HEALTHCARE



Complex pharma synthesis

ELECTRONICS



Integrated circuits

COSMETICS and F&F




Attain required olfactory properties in Perfumes

Cosmetics Ingredients

- **Best-in-class quality non traditional preservatives** (odorless, colorless), with enhanced skin tolerance profile (paraben & phenoxyethanol free)
- **Botanical and biotech active ingredients** (BIO, responsible sourcing, etc.)

COSMETICS




Natural and Green Cosmetics



Beauty brands with major focus on skin health




Strong capabilities and unique expertise to develop and produce highly complex molecules



3 R&D Centers of excellence in Europe and in the US

Main features

Porcheville and Nîmes (France)



Porcheville

- 2 000m²
- 6 Kilo-Labs
- 3 Pilots units (16m³ reaction volume)
- Crystallization/solid state characterization
- 130 scientists with > 50% PhD
- Multidisciplinary teams and ecosystem with a available space for neighbor companies

SEQENS Lab

Nîmes

- Biocatalysis
- Tailor made enzymes

proteus
BY SEQENS

Devens, MA (U.S.)



Key services

Chemistry, Manufacturing and control

- **Supporting your molecules development for a successful submission**
- Right on time delivery
- Quality management
- Regulatory expertise, filing of CEP and DMF
- Compliance

Scale up from early phase to API manufacturing

- Track record on more than 100 entities cGMP or non cGMP
- cGMP Pilot scale (from 1kg up to 80kg) for clinical studies





June 18th 2019 Seqens'Lab unveiling in the presence of Ms Agnès Pannier-Runacher, Secretary of State to the Minister of Economy and Finance



2 000 m²
Lab surface



34 000 m²
Scientific platform




+6M€
Investments since 2017



+10M€/y
Sales of products & services



+120
Employees within 2 years



+5
Innovative companies partnering in Seqens' Lab, incl. :



SEQENS'Lab supports all Seqens Business Units, with two main priorities : Pharma Market & Specialty Ingredients Markets

API process Development

- ✓ Chemical & Biocatalytic Process Development
- ✓ Quality by Design
- ✓ API Crystallization
- ✓ Solid State design & optimization



Significant R&D resources

- > 2,000 m² laboratories, 160 hoods
- 35 chemists & 25 analysts

Safety & EHS studies

- Risk Analysis
- 2 DSC/TGA, 2 calorimetric reactors, 1 calorimeter calvet C80
- 1 adiabatic reactor Phytac II

Analytical development & quality Control

- ✓ API Characterization
- ✓ Method Development
- ✓ Method validation
- ✓ GMP testing
- ✓ GMP release



Strong analytical team and adapted tools for development & validation

- NMR, HPLC, UPLC, UHPLC, LC-MS, GC, GC-MS
- Genotoxic impurities issue solving
- Stability Studies (ICH Guidelines)

API Manufacturing & Supply

- ✓ Scale-up batches : up to 1 kg for pre-clinical studies
- ✓ cGMP Pilot scale : from 1 kg up to 80 kg for clinical studies
- ✓ Regulatory filing



6 Kilo-labs homothetic to pilots

- From -80°C to 200°C

3 pilots units

- 1000 m² surface
- 12 m³ capacity



SEQENS and the French Academy of Sciences

■ Active Scientific Committee:

- Lead by Bernard Meunier former President of the French Academy of Sciences

■ Strong partnership with French Academy of Sciences since two years

- Creation of a "SEQENS Prize*"

*Novacap prize until end 2018



Géraldine MASSON
November 21st, 2017

2nd class Research Director at the CNRS, at the **Institut de Chimie des Substances Naturelles** of Gif-sur-Yvette. Geraldine Masson receive the "SEQENS Prize" for her work on **new and effective methods in the field of catalysis, mainly organic.**

Link to video: <https://www.youtube.com/watch?v=YfQrdZXG7o4>




Julien NICOLAS
October 16th, 2018


Research Director at the CNRS at **the Institut Galien Paris-Sud.** He receive the "SEQENS Prize" for his outstanding contributions to the design of **new Polymers & materials for biomedical applications.**

Link to video:
https://www.youtube.com/watch?v=7o3smtyen_k



Global network of assets on 3 continents committed to development & manufacturing excellence





Our stakeholders

SEQENS is supported by four reference shareholders



Eurazeo is one of the leading listed investment companies in Europe (**€15bn in assets**; listed on Euronext Paris)



Mérieux Développement is an evergreen fund specialized in the healthcare, pharma and nutrition sectors, conducting private equity and venture capital transactions on a global basis. It is an affiliate of Institut Mérieux which is an international pharmaceutical company of c.15,000 employees worldwide and **consolidated revenues exceeding €2.4bn** in 2015

ARDIAN

Ardian (ex Axa Private Equity) is a global independent private investment company (**US\$66bn in assets** managed or advised) which delivers investment performance to its global investors while fueling growth in economies across the world.

EXIMIUM

Eximium is a French leading family office with c. € **500m in assets**, mainly investing in Euronext stocks, private equity investments and real estate.



SEQENS is led by permanent commitment to the society and the world

PUBLIC ENGAGEMENTS



SEQENS- in line with the Union of Chemical industries - complies with the **Charter of Responsible Care** for all of its activities, improving safety, health and environment.




SEQENS signed in 2008 the declaration of the **United Nations Global Compact**, committing itself in supporting the basic principles of human rights, labour laws, environment and to fight against corruption. The pact implies an assessment of the group's best practices on a yearly basis.

COMMITMENTS

SEQENS established a **Sustainable Development Strategy** applicable within the entire group:

- it is based on 3 axis (*People, Planet and Performance*) and 12 detailed commitments) and defines the priorities with its related action plans
- a management systems constantly monitoring its implications thought site correspondents under Group Industrial Direction coordination.





Back-up slides

SEQ2NS

Strong R&D capabilities to develop custom-made and differentiating solutions, to speed up our client's projects by adding value.

Chemistry & analytics

- High performance analytical methods
- Chemistry development
- Biocatalysis
- Purification & solvent recovery
- Design of Experiment
- Quality by Design
- Solid state design & optimization
- Process safety



Biotechnologies

- Native microorganism screenings
- Microorganisms and enzyme engineering
- Customized enzymes production
- Botanical extraction



Drug development services

- Drug repositioning
- Life cycle management of clinical drug candidates
- Tailor-made & high performance polymers for controlled release & medical device



Applicative R&D

- Lubricant additives - applicative testing
- Mineral products - applicative testing:
Pharmaceutical & Healthcare

Cosmetics & Personal Care
Food & Feed
Environment
Home care

